BioCryst Pharma (BCRX) Prix de l'Action, Cotation, Actualités et Historique | Benzinga

BioCryst Pharmaceuticals Inc (BCRX) Prix de l'Action, Cotation, Actualités et Historique

BCRXNASDAQ

Trade with Public

Trade with Public

$8.33

0.060.73%

Dern. MÀJ: Sep 30, 4:40 PM

$8.39

0.121.49%

AperçuActualités Prévisions de résultats Événements Objectifs de cours Données financières Sentiment Actionnariat Comparer Options Rapport sur les stocks

© 2026 Benzinga | All Rights Reserved

Statistiques Clés

Ouverture

-

Clôture

$8.33

Volume / Moy.

97.00 / 4.24M

Fourchette Journalière

- - -

Plage 52 Sem.

6.00 - 11.22

Capitalisation Boursière

$2.14B

Ratio P/E

-

Rendement des Dividendes

-

Échange

NASDAQ

RSI

41

Intérêt à Découvert

13.75%

Jours pour Couvrir

7.29

Actualités Récentes de BioCryst Pharmaceuticals, Inc.

Intuit, Zoom, Qfin Holdings And Other Big Stocks Moving Lower In Wednesday’s Pre-Market Session

US stock futures mixed, Intuit shares dip 11.7% after reporting Q4 revenue of $4.35B and adjusted earnings of $4.03/share. FY27 guidance below estimates. Other stocks moving lower in pre-market trading.

Avi Kapoor

Darden Restaurants To Rally Around 19%? Here Are 10 Top Analyst Forecasts For Tuesday

Wall Street analysts changed outlook on top names. Wedbush raised Replimune's price target, Canaccord cut Strategy's target, Barclays upgraded Watts Water, Rosenblatt boosted Comcast, Goldman increased State Street, Evercore raised Owens Corning, Cantor Fitzgerald boosted BioCryst Pharma, BTIG raised Edwards Lifesciences.

Avi Kapoor

These Analysts Revise Their Forecasts On BioCryst Pharma After Q1 Earnings

BioCryst Pharma (NASDAQ:BCRX) reported strong Q1 earnings, reaffirmed FY2026 sales guidance, and received positive price target changes from analysts.

Avi Kapoor

Why Paranovus Entertainment Technology Shares Are Trading Higher By Around 66%; Here Are 20 Stocks Moving Premarket

PAVS stock rose 65.6% in pre-market trading after ending sales agreement with A.G.P/Alliance Global Partners and other stocks moved.

Avi Kapoor

BioCryst Gets FDA Approval To Treat Rare Childhood Swelling Disorder With Oral Drug

BioCryst secures FDA approval for Orladeyo oral pellets, expanding preventive HAE therapy to children ages 2 to under 12.

Vandana Singh

Données financières

Trimestriel

Annuel

Nom

Revenu Changement
Brut Changement
EBITDA Changement
EBIT Changement
Bénéfices Changement

Flux de Trésorerie

Flux de Trésorerie Opérationnel (TTM)

376.14M

Flux de Trésorerie d'Investissement (TTM)

-448.71M

Flux de Trésorerie de Financement (TTM)

124.63M

Flux de Trésorerie Libre (TTM)

373.38M

Dépenses en Capital (TTM)

-2.76M

Variation Nette de la Trésorerie (TTM)

52.05M

Tendances et prévisions des analystes

2

mai

2

juin

1

1

juil.

2

août

1

1

sept.

Acheter

Conserver

Vendre

Vente forte

Évaluation et prévisions des analystes

3.7

Acheter

Achat fort

Acheter

Conserver

Vendre

Vente forte

Métriques de Valorisation

Valeur Entreprise

$2.57B

Ratio P/E (TTM)

-

Ratio P/E (FWD)

14.12

Ratio PEG (TTM)

-

Ratio P/S (TTM)

2.07

Ratio P/B (TTM)

-

Rendement des Bénéfices % (TTM)

-16.81%

Rendement des Bénéfices % (FWD)

7.08%

EV / EBITDA (TTM)

-

Prix / EBITDA (TTM)

-

Prix / Flux de Trésorerie Libre (TTM)

5.22

Valeur Comptable / Action

-$1.78

Dette Entreprise

Dette Totale

$778.38M

Dette à Long Terme

$778.38M

Émission de Dette à Long Terme (TTM)

$400.00M

Remboursement de la Dette à Long Terme (TTM)

-$232.14M

Trésorerie Totale

$154.97M

Dette sur Capitaux Propres

-

Émission de Dette (TTM)

$167.87M

Remboursement de la Dette (TTM)

-$232.14M